Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 4/20 | 0.98 |
| ▸ | CMA1 | P23946 | 4/20 | 0.98 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.50 |
| ▸ | PDPK1 | O15530 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2123194 | 0.99 | CTSG (1.00) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| Hydrochloric Acid SCHEMBL5117973 | 0.98 | CTSG (0.98) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| Alcohol SCHEMBL3541187 | 0.96 | CTSG (0.95) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| Isopropyl Alcohol SCHEMBL3544252 | 0.96 | CTSG (0.93) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| Sulfuric Acid SCHEMBL5126368 | 0.96 | CTSG (0.93) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| SCHEMBL5118065 | 0.95 | CTSG (0.92) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| Propanol SCHEMBL3540341 | 0.95 | CTSG (0.92) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| SCHEMBL5119379 | 0.90 | CTSG (0.82) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| SCHEMBL5621539 | 0.89 | CTSG (0.82) | CTSGCMA1L3MBTL1PTGDR2PDPK1 | |
| SCHEMBL5622365 | 0.89 | CTSG (0.81) | CTSGCMA1L3MBTL1PTGDR2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7649008-B2 | Crystal of benzimidazole derivative and process for producing the same | TEIJIN PHARMA LIMITED (JP) | 2010-01-19 | — | — | US | claimed |
| US-20060293375-A1 | Crystal of benzimidazole derivative and process for producing the same | TEIJIN PHARMA LIMITED | 2006-12-28 | — | — | US | claimed |
| EP-1626048-A1 | CRYSTAL OF BENZIMIDAZOLE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Teijin Pharma Limited (JP) | 2006-02-15 | — | — | EP | claimed |
| US-10167298-B2 | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof | MERCK SHARP & DOHME CORP. (US) | 2019-01-01 | — | — | US | disclosed |
| US-20160311834-A1 | PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF | MERCK SHARP & DOHME LLC | 2016-10-27 | — | — | US | disclosed |
| US-7649008-B2 | Crystal of benzimidazole derivative and process for producing the same | TEIJIN PHARMA LIMITED (JP) | 2010-01-19 | — | — | US | disclosed |
| US-20060293375-A1 | Crystal of benzimidazole derivative and process for producing the same | TEIJIN PHARMA LIMITED | 2006-12-28 | — | — | US | disclosed |
| EP-1626048-A1 | CRYSTAL OF BENZIMIDAZOLE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Teijin Pharma Limited (JP) | 2006-02-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10167298-B2 | Pseudopolymorphs of an HCV NS5A inhibitor and uses thereof | POLI, HAVCR2, EIF2AK2 | CTSG 2090/4885CMA1 2827/4885L3MBTL1 2224/4885 |
| US-20160311834-A1 | PSEUDOPOLYMORPHS OF AN HCV NS5A INHIBITOR AND USES THEREOF | POLI, HAVCR2, EIF2AK2 | CTSG 2090/4885CMA1 2827/4885L3MBTL1 2224/4885 |
| US-20060293375-A1 | Crystal of benzimidazole derivative and process for producing the same | ABAT, DBI, BRI3BP | CTSG 4148/4885CMA1 1635/4885L3MBTL1 1588/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.